Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Electroacupuncture, Olanzapine-contained...
Phase PHASE3
Enrollment 370
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Electroacupuncture — The acupuncturists will insert needles into the acupoints and manipulate the needles until"de qi"sensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz.
  • Drug: Standard antiemetic treatment — Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
  • Device: Sham electroacupuncture — The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid "de qi" sensation.
  • Drug: Standard antiemetic treatment — Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.

Primary Outcomes

  • Proportion of patients with no nausea during the overall stage (120 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-01-16
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 370 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiuda Zhao
Contact Information
Study Contact:
Jiuda Zhao, Dr
869716230893
jiudazhao@126.com
Qinghai University Affiliated Hospital
Interventions
  • Device: Electroacupuncture — The acupuncturists will insert needles into the acupoints and manipulate the needles until"de qi"sensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz.
  • Drug: Standard antiemetic treatment — Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
  • Device: Sham electroacupuncture — The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid "de qi" sensation.
  • Drug: Standard antiemetic treatment — Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
Study Locations (1 sites)
Qinghai University Affiliated Hospital, Xining, Qinghai 810000 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older and aged 75 years or younger, of any nationality; 2. Eastern Cooperative Oncology Group performance status of 0-2; 3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin; 4. Predicted life expectancy of ≥3 months; 5. Adequate bone marrow, kidney, and liver function; 6. Adequate contraception if premenopausal women; 7. Written informed consent by the patient before enrolment. Exclusion Criteria: 1. Patients already submitted to chemotherapy; 2. Is scheduled to receive any non-HEC on Day 1; 3. Is scheduled to receive any chemotherapy on days 2-4 after HEC; 4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1; 5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting; 6. Have ongoing emesis or CTCAE grade 2 or greater nausea; 7. Significant medical or mental conditions; 8. Any allergies to study drug, antiemetics or dexamethasone; 9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine); 10. Patients who are pregnant or breast-feeding; 11. Inflammatory skin reaction; 12. Has lymphedema in acupuncture stimulation area; 13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles; 14. Received acupuncture treatments for any conditions less than 4 weeks before HEC; 15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation)); 16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis; 17. Has a convulsive disorder requiring anticonvulsant treatment; 18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment); 19. Concurrent treatment with quinolone antibiotics; 20. Has a history of chronic alcoholism (determined by the investigator); 21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months; 22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).
Conditions Breast Cancer (Locally Advanced or Metas...
Phase PHASE1, PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Dual-target CAR-NK cells (EB-DT-CAR-NK) — Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.
  • Drug: Lymphodepleting chemotherapy — fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.
  • Other: Supportive care — Premedication per institutional standard (e.g., acetaminophen and antihistamine). Tumor lysis and infection prophylaxis per institutional guidelines.

Primary Outcomes

  • Incidence of dose-limiting toxicities (DLTs) (28 Days)
  • Safety profile (12 months)
  • Recommended Phase 2 Dose (56 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-02-02
Completion: 2028-03-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Biotech
Contact Information
Study Contact:
Seni S Lu, Phd
+86 13076790030
Seni-Lu@beijing-biotech.com
Zhen J Peng, Phd
+8613076790039
Zhen-Peng@beijing-biotech.com
Peking University Shenzhen Hospital
Interventions
  • Biological: Dual-target CAR-NK cells (EB-DT-CAR-NK) — Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.
  • Drug: Lymphodepleting chemotherapy — fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.
  • Other: Supportive care — Premedication per institutional standard (e.g., acetaminophen and antihistamine). Tumor lysis and infection prophylaxis per institutional guidelines.
Study Locations (1 sites)
Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036 China
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed breast carcinoma that is locally advanced, unresectable, or metastatic. * Disease subtype: HER2-positive breast cancer or triple-negative breast cancer (TNBC). * Progression after, intolerance to, or ineligibility for standard therapies appropriate for the disease subtype and line of therapy. * At least one measurable lesion per RECIST v1.1. * Tumor antigen assessment available (fresh or archival): expression of at least one candidate target antigen (HER2/ERBB2, MUC1, or ROR1). For TNBC, mesothelin assessment may be performed for exploratory analyses. * ECOG performance status 0-1. * Adequate organ function (example thresholds): ANC ≥ 1.0 x 10\^9/L; platelets ≥ 75 x 10\^9/L; hemoglobin * 8 g/dL; AST/ALT ≤ 3x ULN (≤ 5x with liver metastases); total bilirubin ≤ 1.5x ULN; creatinine clearance * 50 mL/min. * Left ventricular ejection fraction (LVEF) ≥ 45% and no uncontrolled cardiac arrhythmia. * Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception during study treatment and for 6 months after last CAR-NK infusion. * Ability to understand and willingness to sign informed consent. Exclusion Criteria: * Active, untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with treated CNS metastases may be eligible if clinically stable for ≥ 4 weeks and off high-dose steroids. * Prior gene-modified cellular therapy (e.g., CAR-T or CAR-NK) within 6 months or unresolved grade ≥ 2 toxicity from prior cellular therapy. * Clinically significant active autoimmune disease requiring systemic immunosuppression (physiologic steroid replacement permitted). * Uncontrolled infection, including uncontrolled HBV, HCV, or HIV infection (controlled infections may be eligible per investigator). * History of severe hypersensitivity to fludarabine or cyclophosphamide. * Pregnant or breastfeeding. * Concurrent participation in another interventional study that could confound safety or efficacy assessments. * Any condition that, in the investigator's judgment, would make the participant unsuitable for the study (e.g., uncontrolled comorbidity, inability to comply with protocol procedures).
Conditions Breast Cancer Patients
Phase Not Applicable
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Prospective Evaluation of the Efficacy and Safety of Prepectoral Immediate One-Stage Prosthetic Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Breast Reconstruction Surgery — Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy

Primary Outcomes

  • BREAST-Q (Breast Reconstruction Module) Scores (Preoperatively and at 1 Year Postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-20
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Principal Investigators:
  • xiuchun chen (STUDY_DIRECTOR) - Henan Cancer Hospital
Contact Information
Study Contact:
xiuchun Chen
18603719919
cxc701024@163.com
minhao Lv
13838392355
lvminhao2004628@163.com
Chen chun
Henan cacer hospital
Interventions
  • Procedure: Breast Reconstruction Surgery — Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy
Study Locations (1 sites)
Henan cacer hospital, Henan, Henan 450008 China
Eligibility Criteria
Inclusion Criteria: 1. women aged 18 to 70; 2. Newly diagnosed breast cancer patients showing no evidence of distant metastasis on clinical examination and diagnostic workup; 3. adjuvant radiotherapy is required; 4. Patients scheduled to undergo nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) with immediate prepectoral implant-based reconstruction (via open, endoscopic, or robotic approach) require adjuvant radiotherapy AFTER permanent implant placement; OR Patients scheduled for NSM/SSM with two-stage tissue expander/implant reconstruction (with expander placement in either submuscular or prepectoral plane) receive radiotherapy WITH the tissue expander in situ, followed by exchange for permanent implant ≥6 months post-radiotherapy (expander position: submuscular/prepectoral acceptable; surgical approach: open/endoscopic/robotic acceptable); 5. Patients are eligible regardless of whether mesh is used in the reconstruction surgery; 6. Patients with severe breast ptosis are eligible; 7. During the study observation period, lipofilling is permitted on the affected breast and symmetrization procedures on the contralateral breast in both cohorts; 8. ECOG performance status 0-1; 9. Patients receiving neoadjuvant chemotherapy (NACT) are eligible; 10. Bilateral breast reconstruction is permitted; 11. No smoking history OR smoking cessation ≥4 weeks prior to enrollment; 12. Investigator-confirmed protocol compliance capability; 13. Concurrent participation in other interventional/non-interventional trials is allowed if deemed non-interfering by the investigator; 14. Voluntarily participate and sign the informed consent form after comprehensive understanding. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer; 2. No prior radiotherapy post-mastectomy; 3. History of ipsilateral chest wall/axillary radiation therapy; 4. Immunodeficiency, poorly controlled diabetes (HbA1c \>7%), or active tobacco use; 5. Inflammatory breast cancer (cT4d); 6. Autologous-based breast reconstruction or delayed reconstruction; 7. Severe cardiopulmonary/hepatic/renal comorbidities contraindicating surgery/radiotherapy (ASA class ≥III); 8. Psychiatric disorders precluding independent BREAST-Q completion; 9. Pregnancy or lactation; 10. Documented history of protocol non-adherence; 11. Life-limiting comorbidities interfering with treatment OR investigator-determined ineligibility.
Conditions Advanced Solid Tumor
Phase PHASE1
Enrollment 52
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CX-5461 — 150 mg sterile lyophilized powder containing 1% sucrose

Primary Outcomes

  • Determination of Recommended Phase 2 Dose (RP2D) (Safety cohort review will be conducted every 4 weeks from the date of first patient's enrollment to review safety data, until all patients have been enrolled and evaluated for toxicity.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-09-08
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Senhwa Biosciences, Inc.
Principal Investigators:
  • Jason Huang, MD (STUDY_DIRECTOR) - Senhwa Biosciences
Contact Information
Study Contact:
Hylee Lee
886-2-889119856
hylee@senhwabio.com
Jenny Chen
jennychen@senhwabio.com
Lee Rosen, MD
University of California, Los Angeles
Interventions
  • Drug: CX-5461 — 150 mg sterile lyophilized powder containing 1% sucrose
Study Locations (8 sites)
University of California, Los Angeles, Santa Monica, California 90404 United States
H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida 33612-9497 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
Memorial Sloan-Kettering Cancer Center, New York, New York 10065 United States
Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio 43202 United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232 United States
Princess Margaret Cancer Centre, Toronto, Ontario M5G 1X6 Canada
Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec H2X 0C2 Canada
Eligibility Criteria
Inclusion Criteria: Main study cohort: 1. Histologically or cytologically confirmed malignancy of the pancreas, prostate, breast, or ovary. 2. Documented evidence of pathogenic or likely pathogenic somatic or germline mutation in BRCA1/2 and/or PALB2, and/or any genetic alterations listed below as indicated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory report. The report must be submitted to and approved by study sponsor prior to registration. Other HRD-associated mutations could be eligible if prior approval by the sponsor is granted. ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CCNE1, CHEK1, CHEK2, CDK12, CREBBP, FANCA, FANCI, FANCL, FANC2, FANCB, FANCC, FANCD2, FANC family\*, MRE11A, MYC, NBN, NCL, PALB2, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, SLFN11, PTIP, MLL3, MLL4, EZH2, CtIP(RBBP8), MUS81, CDH4, DYNLL11, TOPBP1, NBS1, CDC25A, CDC25C, RAD17, WEE1 \* In addition to the genes already specified, the "FANC family" genes may also include the following: FANCE, FANCF, FANCG, FANCM, FANCP, FANCQ/ERCC4/XPF, FANCR/RAD51, FANCT/UBE2T, FANCU/XRCC2, FANCV/REV7/MAD2L2, and FANCW/RFWD3. Exploratory cohort: 1. Histologically confirmed ovarian, fallopian tube or primary peritoneal cancer, with a high grade serous or high grade endometrioid histology subtype. 2. Documented evidence of pathogenic or likely pathogenic germline mutation or a clinically actionable somatic mutation in BRCA1 and/or other HRD-associated mutation, as indicated in a CLIA-certified laboratory report. The report must be submitted to and approved by study sponsor prior to registration. 3. Meet one of the following criteria: 1. Platinum Sensitive with no evidence of disease progression within 6 months of the last dose of platinum-based chemotherapy (n=10 patients); OR 2. Platinum Resistant with disease progression within 6 months of the last dose of a platinum-based chemotherapy. All participants: 1. Age ≥ 18 years. 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 14 days of registration. 3. Radiographically documented disease progression within 28 days of registration and evaluable as per RECIST v1.1. 4. Patient must have measurable disease as per RECIST v1.1. 5. Patients must have adequate bone marrow, renal and hepatic function per local laboratory reference ranges as follows within 14 days of registration: 1. Absolute Neutrophil Count ≥ 1.5 x 10\^9/L 2. Platelets ≥ 100 x 10\^9/L 3. Hemoglobin ≥ 9 g/dL (blood transfusion ≤ 7 days of screening not permitted). 4. Calculated creatinine clearance \> 51mL/min (Cockcroft-Gault formula) 5. AST/ALT ≤ 2.5× the upper limit of normal (ULN). Subjects with liver metastasis may have AST, ALP, and ALT ≤ 5.0 X ULN. 6. Bilirubin ≤ 1.5×ULN. This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology), who will be allowed only at the discretion of the Study Investigator. 7. INR/PT and aPTT ≤1.5 X ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants. 8. Albumin ≥3.0 g/dL 6. Patients are willing to undergo tumour biopsy pre-treatment and at time of progression on treatment. If a biopsy at the time of progression on prior therapy is available and can be submitted to the Central Lab for this study, this procedure does not need to be repeated. Patients who consent but have tumour that is not amenable to safe biopsy will be allowed to enter the trial and continue therapy as per protocol if this has been addressed and permission is granted from the sponsor prior to registration. 7. Life expectancy of greater than 3 months from the date of registration. 8. Able to provide written informed consent. 9. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. 10. Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. (Note: a negative urine/serum pregnancy test is required on Cycle 1, Day 1 prior to treatment unless the screening pregnancy test was done within 48hrs of registration). 11. Female patients of childbearing potential and male patients who are sexually active must agree to practice true abstinence or at least two effective methods of contraception (ie: condoms with spermicide, hormonal methods such as oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs), non-hormonal IUDs, such as ParaGard, bilateral tubal ligation, vasectomy, complete abstinence) within 14 days prior to registration, and agree to continue using such precautions while on treatment with CX-5461 (including dose interruptions) and for 6 months following the last dose of CX-5461. 12. There is no minimum or maximum number of lines of prior therapy and prior PARP inhibitor therapy is allowed. 13. Patient is clinically stable at the time of entering the study. Exclusion Criteria: 1. For pancreatic cancer; non-adenocarcinoma histology is excluded from this study. 2. Patients with malignant bowel obstruction. 3. Untreated, unstable brain or meningeal metastases or tumor. Patients with radiological evidence of stable brain metastases are eligible provided that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilization at least 10 days after discontinuation of steroids. 4. Unresolved toxicity \> CTCAE grade 1 from previous anti-cancer therapy (including radiotherapy) except hematological toxicity, Grade 1 or 2 neuropathy, and alopecia. 5. Any evidence of severe or uncontrolled diseases such as but not limited to active infection, unstable or uncompensated respiratory, cardiac, neurological, hepatic, renal disease or psychiatric illness/social situations, which in the opinion of the investigator, would limit compliance with study requirements. 6. Treatment with an investigational (non-registered - other than PARP inhibitor) agent within 30 days and treatment with PARP inhibitor within 14 days prior to the first dose of study medication. 7. Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e., hepatitis B or C). Note: Patients with a prior history of treated HBV infection who are antigen-negative or patients with a prior history of treated HCV infection who are HCV RNA-undetectable may be enrolled. Patients who are known to be serologically positive for human immunodeficiency virus (HIV) can enroll if their CD4+ T-cell (CD4+) counts ≥ 350 cells/uL. 8. Patients who have had recent (within 14 days of registration, or until any wound has completely healed) major thoracic or abdominal surgery prior to study start, or a surgical incision that is not fully healed. 9. No concurrent systemic anti-cancer therapy, biological therapy or other novel agent is to be permitted. Palliative radiotherapy may be allowed. If radiotherapy is required due to disease progression, patient will be considered off study. If radiotherapy is be used to treat non-target lesions and patients may benefit from continuing on study treatment, CX-5461 may re-commence 14 days after completion of radiotherapy. Any continuation on study treatment must be discussed with and approved by study sponsor. 10. Patients may be potentially eligible where the current tissue diagnosis is confirmed histologically from biopsy of a target lesion, and the patient has had no evidence of active second malignancy which requires treatment or would confound interpretation of safety, tolerability and efficacy of CX-5461. These cases must be discussed with the medical monitor prior to confirm eligibility. 11. Presen
Conditions Breast Cancer
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Human trophoblast cell-surface glycoprotein antigen 2 (Trop2) is a membrane surface receptor that plays an important role in the occurrence and development of tumors. Studies have shown that Trop2 is highly expressed in a variety of cancers (such as breast cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer, and ovarian cancer, etc.) and is related to the proliferation, invasion, and metastasis of tumor cells. and other processes related. According to statistics, more than 80% of breast cancer patients highly express Trop2, and high expression of Trop2 is positively correlated with shortened survival and poor prognosis of cancer patients. In this study, a single-domain antibody targeting Trop2 was selected to prepare a new nuclear medicine molecular probe 99mTc-MY6349, so as to monitor the expression level of Trop2 in patients' systemic tumors through SPECT/CT imaging. Breast cancer patients who intend to use gosatuzumab for subsequent treatment can first undergo 99mTc-MY6349 SPECT/CT imaging to detect Trop2 expression levels in systemic tumors. Subsequently, 18F-FDG PET/CT imaging was performed to compare and detect the distribution of primary tumors and systemic metastases in patients with breast cancer. This study analyzes the heterogeneity of Trop2 expression levels within the primary tumor and the heterogeneity of expression levels in systemic metastases, thereby providing a basis for testing whether the patient is suitable for subsequent treatment and conducive to the formulation of subsequent treatment plans.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 99mTc-MY6349 SPECT/CT scan — Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.

Primary Outcomes

  • semi-quantitative analysis (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-13
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Li Huo (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Li Huo
86-13910801986
huoli@pumch.cn
Li Huo
86-13910801986
huoli@pumch.cn
Peking Union Medical College Hospital
Interventions
  • Diagnostic Test: 99mTc-MY6349 SPECT/CT scan — Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100730 China
Eligibility Criteria
Inclusion Criteria: * Female, aged between 18 and 80 years old. * Patients with suspected or definite diagnosis of triple-negative breast cancer. * Patients with suspected or confirmed triple-negative recurrent or metastatic breast cancer. * Female subjects must have medical records to prove that they have undergone surgical sterilization (such as hysterectomy, bilateral oophorectomy, or tubal ligation) or have been menopausal for more than one year; if they still have the ability to conceive, isolation contraceptive measures must be taken during this study period. Exclusion Criteria: * Suffering from severe gastrointestinal, cardiovascular, liver, kidney, blood system, endocrine, respiratory system, immune deficiency and other serious diseases. * Claustrophobia. * In the past year, due to other clinical medical treatment or scientific research needs, received ionizing radiation outside the scope of this experiment, so that the annual radiation exposure dose exceeded 50mSv. * Pregnant or lactating women. * Received experimental drug or device treatment (with unclear efficacy or safety) within 1 month. * There is any situation in which the conductor of this study believes that any aspect related to this experiment may cause harm or be potentially harmful.

Breast Cancer PSMA PET

NCT06586047
Recruiting
Conditions Triple Negative Breast Cancer
Phase EARLY_PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: PET imaging — Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer

Primary Outcomes

  • Lesion detection sensitivity analysis (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-08-29
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ahmad Shariftabrizi
Collaborators: Progenics Pharmaceuticals, Inc.
Contact Information
Study Contact:
Ahmad Shariftabrizi, M.D.
319-887-4942
ashariftabrizi@uiowa.edu
Elina Shrestha
319 335 0114
eshrestha@uiowa.edu
Ahmad Shariftabrizi, M.D.
319-887-4942
ashariftabrizi@uiowa.edu
University of Iowa Healthcare
Interventions
  • Diagnostic Test: PET imaging — Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer
Study Locations (1 sites)
University of Iowa Healthcare, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with known active other malignancy. * Unable to tolerate PET/CT procedure. * Pregnant or breastfeeding. * Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of the study is to evaluate the feasibility, acceptability and preliminary effects of the next iteration of iCareBreast+, an innovative breast care e-support intervention programme, by refining existing contents and building new contents based on comprehensive assessment of breast cancer women's needs and preferences among breast cancer patients undergoing chemotherapy. The specific objectives of this study are: 1. To develop a new iteration of an innovative smartphone-based self-care solution for patients with breast cancer undergoing chemotherapy (iCareBreast+); 2. To assess the feasibility and acceptability of iCareBreast+; and 3. To explore the preliminary effects of iCareBreast+ on the primary outcome of self-efficacy, and knowledge of breast cancer treatment, as well as secondary outcomes including anxiety, depression, health-related quality of life (HRQoL), social support and satisfaction with oncologic care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Routine care — Routine care provided by NCCS
  • Other: Routine care + iCareBreast+ mobile app — Routine care provided by NCCS (identical to the control group) along with access to the iCareBreast+ mobile app

Primary Outcomes

  • The feasibility of research method and Intervention (Throughout data collection period, estimated up to six months or until last subject with last visit completion whichever is later.)
  • The acceptability of intervention (After intervention (two months immediately post intervention))
  • The impact of psychosocial intervention (iCareBreast+ app) on cancer self-efficacy (Baseline (on enrolment day), and after Intervention (two months immediately post intervention))
  • The impact of psychosocial Intervention (iCareBreast+ app) on knowledge of breast cancer treatment (Baseline (on enrolment day), and after Intervention (two months immediately post intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-23
Completion: 2025-10-31
Eligibility
Age: 21 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Centre, Singapore
Collaborators: Buddy Healthcare Ltd OY
Principal Investigators:
  • Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed (PRINCIPAL_INVESTIGATOR) - National Cancer Centre, Singapore
Contact Information
Study Contact:
Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed
+65 64368000
ryan.shea.tan.y.c@singhealth.com.sg
Bernard JG Chua, MBBS (Hons)(Aus), MRCP (UK)
+65 64368000
bernard.chua.j.g@singhealth.com.sg
Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed
National Cancer Centre, Singapore
Interventions
  • Other: Routine care — Routine care provided by NCCS
  • Other: Routine care + iCareBreast+ mobile app — Routine care provided by NCCS (identical to the control group) along with access to the iCareBreast+ mobile app
Study Locations (1 sites)
National Cancer Centre, Singapore, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: Women who: * are the age of 21 years old and above at the point of recruitment; * are diagnosed with stage 1-3 breast cancer; * will undergo chemotherapy first time (initiating or up to #4 cycles of chemo is acceptable); * can speak, read and write in English or Mandarin; and * has access to and able to use smart phone. Exclusion Criteria: Those who : * are with a history of or concurrent other cancer types; * have been suffering from psychiatric illness (e.g., schizophrenia), anxiety disorder or other mood disorder or impaired cognitive function; * have alcohol or substance abuse within the previous year; * are undergoing concurrent psychosocial interventions; and * have been in the bereavement period in the last 6 months * are in their pregnancy.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase EARLY_PHASE1
Enrollment 40
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This early phase I trial tests whether letrozole with simvastatin works better than letrozole alone to stop tumor cell proliferation in patients with stage I-III hormone receptor positive, HER2 negative invasive breast cancer. Letrozole and simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The addition of simvastatin to letrozole may be more effective at stopping the growth of cancer cells than letrozole alone.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Letrozole — Given PO
  • Drug: Simvastatin — Given PO

Primary Outcomes

  • Mean percentage change in Ki-67 (From pre-surgical baseline to 14 days following preoperative therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2022-09-02
Completion: 2028-04-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Ruth L. Sacks, MD (PRINCIPAL_INVESTIGATOR) - Emory University Hospital/Winship Cancer Institute
Contact Information
Study Contact:
Ruth L. Sacks, MD
404-778-1345
ruth.lauren.sacks@emory.edu
Obi Ezennia
obichukwu.ezennia@emory.edu
Grady Healthcare System
Ruth Sacks, MD
Grady Healthcare System
Interventions
  • Drug: Letrozole — Given PO
  • Drug: Simvastatin — Given PO
Study Locations (4 sites)
Grady Healthcare System, Atlanta, Georgia 30303 United States
Emory University Hospital Midtown, Atlanta, Georgia 30308 United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States
Emory Saint Joseph's Hospital, Atlanta, Georgia 30342 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Biopsy proven hormone receptor positive, HER2 negative stage I-III invasive breast cancer * Estrogen receptor (ER) and/or progesterone receptor (PR) positivity are defined as \>= 10% of cells expressing hormonal receptors via IHC analysis * HER2 negativity is defined as either of the following by local laboratory assessment * IHC 0, 1+, or 2+ and in situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell) * Minimum primary tumor size 5 mm on any breast imaging (mammogram, ultrasound, magnetic resonance imaging \[MRI\]) * Baseline Ki-67 IHC expression on tumor tissue \>= 10% * Post-menopausal women * Prior bilateral oophorectomy * Age \>= 55 years * Age \< 55 and amenorrheic for 12 months or more in the absence of chemotherapy, endocrine therapy, or ovarian suppression and follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol in the postmenopausal range * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Prior treatment: * No systemic therapy (chemotherapy, immunotherapy, endocrine therapy, and/or investigational therapy) within 3 months of trial enrollment * No statins, fibrates, or ezetimibe within 3 months of trial enrollment * No active liver disease * Hemoglobin \>= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 9.0 g/dl is acceptable) (within 14 days prior to initiation of study treatment) * Absolute neutrophil count (ANC) \>= 1,500/mcL (after at least 7 days without growth factor support or transfusion) (within 14 days prior to initiation of study treatment) * Platelets \>= 100,000/mcL (within 14 days prior to initiation of study treatment) * Total bilirubin =\< 2 institutional upper limit of normal (ULN) (within 14 days prior to initiation of study treatment) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 institutional ULN (within 14 days prior to initiation of study treatment) * Serum creatinine =\< 2 mg/dL (or glomerular filtration rate \>= 40 mL/min) (within 14 days prior to initiation of study treatment) * Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions * Be willing and able to provide written informed consent for the trial Exclusion Criteria: * Patients who are receiving any other investigational agents or an investigational device within 3 months before administration of first dose of study drugs * History of allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin and/or letrozole * Concomitant use of strong CYP3A4 inhibitors (i.e. clarithromycin, erythromycin, itraconazole, ketroconazole, nefazodone, Posaconazole, voriconazole, protease inhibitors \[including boceprevir and telaprevir\], telithromycin, cobicistat-containing products), cyclosporine, danazol, and gemfibrozil * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, substance abuse disorders, or psychiatric illness/social situations that would limit compliance with study requirements * Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association class 3 or 4 congestive heart failure; or uncontrolled grade \>= 3 hypertension (diastolic blood pressure \>= 100 mmHg or systolic blood pressure \>= 160 mmHg) despite antihypertensive therapy * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE2
Enrollment 11
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well cemiplimab and transarterial radioembolization (TARE) with yttrium-90 (Y90) SIR-Spheres, registered trademark, works in treating breast cancer that has spread from where it first started (primary site) to the liver (metastatic). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. TARE is a treatment that uses radioactive microspheres, such as Y90 SIR-S Spheres, to both cause hepatic artery embolization and to deliver regional radiotherapy. Y90 SIR-S Spheres is an injectable form of the radioisotope yttrium Y 90 encapsulated in resin microspheres. When injected into the artery supplying the tumor, yttrium Y 90 resin microspheres block the tumor blood vessels and deliver the yttrium Y 90 directly to the tumor site, which may kill or slow tumor growth. Giving cemiplimab and Y90 SIR-Spheres by TARE to the tumor in the liver may kill more tumor cells in patients with metastatic breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Biological: Cemiplimab — Given IV
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Radiation: Transarterial Radioembolization — Undergo TARE
  • Radiation: Yttrium Y 90 Resin Microspheres — Given intratumorally

Primary Outcomes

  • CD8+ T cell infiltration in tumor microenvironment (TME): baseline (At baseline)
  • CD8+ T cell infiltration in tumor microenvironment (TME): post TARE -1 (day 21) (At Post-transarterial radioembolization TARE -1 (day 21))
  • CD8+ T cell infiltration in tumor microenvironment (TME): prior to TARE-2 (day 42) (At prior to TARE-2 (day 42))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-30
Completion: 2027-01-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Jonathan Kessler (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Jonathan Kessler
626-218-8398
jkessler@coh.org
City of Hope Medical Center
Jonathan Kessler
City of Hope Medical Center
Interventions
  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Biological: Cemiplimab — Given IV
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
Study Locations (1 sites)
City of Hope Medical Center, Duarte, California 91010 United States
Eligibility Criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) 0-1 * Must have a life expectancy of at least 12 weeks * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy) * Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner then must be using an acceptable form of contraception * Patients with metastatic breast cancer, previously treated with ≥ 1 line of chemotherapy in metastatic setting * Candidate for TARE based on evaluation by board certified interventional radiologist; must have measurable metastatic liver disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in RECIST version 1.1; not all liver tumors will be treated with TARE in a single session * Liver tumor burden \< 50% * No radiographic or clinical evidence of cirrhosis * Other treated stable metastases are allowed, including treated stable brain metastases * Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy * Body weight \> 30 kg * No untreated, active hepatitis * Hemoglobin ≥ 9.0 g/dL (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Absolute neutrophil count (ANC) ≥ 1500/uL (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Platelet count ≥ 75000/uL (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Total bilirubin \< 2.0mg/dL (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT/serum glutamic pyruvic transaminase \[SGPT\]) ≤ 5 x upper limit of normal (ULN) (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Albumin ≥ 2.8 g/dL (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * International normalized ration (INR) ≤ 1.6 (within 14 days prior to day 1 of protocol therapy unless otherwise stated) * Measured creatinine clearance (CL) \> 40 mL/min or calculated creatinine CL \> 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (within 14 days prior to day 1 of protocol therapy unless otherwise stated) Exclusion Criteria: * Prior immunotherapy in the past 12 months * Progressing or untreated extra-hepatic metastatic disease * Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring immunosuppressive therapy * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Portal vein invasion * Evidence of diffuse metastatic disease (tumor burden occupying \> 50% of liver) * Major surgical procedure (as defined by the investigator) within 28 days prior to radioembolization. Note: Local surgery of isolated lesions for palliative intent is acceptable * Participation in another clinical study with an investigational product during the last 4 weeks * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study * Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) ≤ 28 days prior to the first dose of study drug. If sufficient wash-out time has not occurred due to the schedule or pharmacokinetics (PK) properties of an agent, a longer wash-out period will be required, as agreed by Regeneron and the investigator * Prior exposure to anti-PD-1/PD-L1 inhibitor or anti-CTLA4 inhibitor, including cemiplimab in the past 12 months * Any unresolved toxicity National Cancer Institute (NCI) CTCAE grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria * Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with cemiplimab may be included only after consultation with the study physician * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\]). The following are exceptions to this criterion: Patients with vitiligo or alopecia; patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; any chronic skin condition that does not require systemic therapy; patients without active disease in the last 5 years may be included but only after consultation with the study physician; patients with celiac disease that is controlled by diet alone * History of allogeneic organ transplantation * Expected radiation lung dose of \> 30Gy * Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent * History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study treatment and of low potential risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * History of active primary immunodeficiency or acquired human immunodeficiency virus (HIV/AIDS) * Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment * Active systemic infection including tuberculosis (clinical evaluati
Conditions Breast Cancer
Phase Not Applicable
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from the cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis. Clinical studies have provided initial evidence that EVs may have a prognostic and predictive value in breast cancer. Considering their presence in body fluids and their minimally invasive assessment through blood sampling, EVs could be liquid biopsy-derived biomarkers. Their quantification could be a complex challenge, requiring complicated and time-consuming pre-analytical procedures of EVs isolation. A new method for the detection of tumor-derived-EVs associated proteins is based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles. The aim of this study is to evaluate how this new technology can allow the quantification EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information about the efficacy of the neoadjuvant treatment.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • EVs levels (78 months)
  • EVs levels in time (78 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-05-11
Completion: 2027-12-21
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Contact Information
Study Contact:
Fabio S Corsi, Professor
+390382592272
fabio.corsi@icsmaugeri.it
SARA PAOLA ALBASINI, MsC
+393497378405
sara.albasini@icsmaugeri.it
Fabio Corsi, Professor
0382592272
fabio.corsi@icsmaugeri.it
Istituti Clinici Scientifici Maugeri SpA
Interventions
N/A
Study Locations (1 sites)
Istituti Clinici Scientifici Maugeri SpA, Pavia, Lombardy 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Signing of a specific informed consent for participation to the study * Female sex BC patients: * Diagnosis of breast cancer * Any TNM stage * Indication to neoadjuvant chemotherapy after multidisciplinary discussion Healthy controls: • Patients with a negative mammography, breast ultrasound or clinical breast evaluation within 12 months of the study enrolment Exclusion Criteria: BC patients: • Indication to upfront surgery Healthy controls: • Diagnosis of breast cancer
Conditions Breast Cancer, Cancer of the Breast
Phase NA
Enrollment 410
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

In this study, patients who are scheduled for breast reconstruction consultation will be randomized into the intervention group (ChatGPT-generated patient education regarding possible reconstruction options) or the control group (usual patient education). All patients will complete a survey following their in-person consultation to assess their experience and overall satisfaction with the consultation process. Additionally, participating surgeons will complete a separate survey to evaluate their consultation experience, satisfaction, and to assess the accuracy and clinical utility of the ChatGPT-generated patient education materials. The surveys are designed to gather information on patient characteristics, organizational health literacy according to Brega et al. Other survey questions have been designed to meet the outcomes of this study and have not been based on previously published surveys.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Other: ChatGPT-generated patient education — This is created by entering the patient's age, medical history, social history, and case-specific details into Washington University ChatGPT Beta (HIPAA and FERPA compliant) by a study team member.
  • Other: Usual patient education — Usual patient education will include description of breast reconstruction options, with further elaboration on which option are more suitable to the patient. This include also review of risk of complications and expected recovery after surgery.

Primary Outcomes

  • Patient perceived understanding of breast reconstruction (Pre-surgical consultation (day 1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-03
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 410 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • Saif M Badran, M.D., Ph.D., FRCS (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Saif M Badran, M.D., Ph.D., FRCS
314-273-1434
badran@wustl.edu
Saif M Badran, M.D., Ph.D., FRCS
314-273-1434
badran@wustl.edu
Washington University School of Medicine
Saif M Badran, M.D., Ph.D., FRCS
Washington University School of Medicine
Interventions
  • Other: ChatGPT-generated patient education — This is created by entering the patient's age, medical history, social history, and case-specific details into Washington University ChatGPT Beta (HIPAA and FERPA compliant) by a study team member.
  • Other: Usual patient education — Usual patient education will include description of breast reconstruction options, with further elaboration on which option are more suitable to the patient. This include also review of risk of complications and expected recovery after surgery.
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Patient Eligibility Criteria: * Scheduled for initial preoperative breast reconstruction consultation following therapeutic or prophylactic mastectomy with a surgeon at Washington University School of Medicine. * At least 18 years of age. * Can speak and understand English. Surgeon Eligibility Criteria: * Routinely performs breast reconstruction surgery at Washington University School of Medicine. * At least 18 years of age. * Can speak and understand English. * Surgeon must not be a resident or fellow at time of enrollment.
Conditions Breast Cancer
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to decrease undesirable side effects and increase qulaity of life of aromatase inhibitors therapy in breast cancer survivors, by anti-inflammatory diet or supplementation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Supplement — Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
  • Dietary Supplement: AI diet — diet rich in whole grains, healthy oils and polyphenols,
  • Dietary Supplement: Placebo — Placebo caps with standard diet

Primary Outcomes

  • Nutritional status (baseline, 4 months, 1 year)
  • Nutritional status (baseline, 4 months, 1 year)
  • Nutritional status (baseline, 4 months, 1 year)
  • Changes in Quality of life (baseline, 4 months)
  • Changes in Quality of life (baseline, 4 months)
  • Changes in Quality of life (baseline, 4 months)
  • Clinical outcome (baseline, 4 months, 1 year)
  • Clinical outcome (baseline, 4 months, 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2026-11-30
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Belgrade
Contact Information
Study Contact:
Nebojsa Ivanovic, Dr
0603947871
ivanovicnebojsadr@gmail.com
Clinical Hospital Center Bezanijska kosa
Vesna Vucic, PhD
+381113031997
vesna.vucic.imr@gmail.com
Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade
Danijela Ristic Medic, MD PhD
Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade
Interventions
  • Dietary Supplement: Supplement — Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
  • Dietary Supplement: AI diet — diet rich in whole grains, healthy oils and polyphenols,
  • Dietary Supplement: Placebo — Placebo caps with standard diet
Study Locations (2 sites)
Clinical Hospital Center Bezanijska kosa, Belgrade, 11070 Serbia
Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Belgrade, 11129 Serbia
Eligibility Criteria
Inclusion Criteria: * Age: 45 to 70 years * Postmenopausal women * Histologically confirmed BRC, stage I to IIIa * ER positive /HER2 negative * Application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months * Body mass index from 20 to 34.9 kg/m 2 * Able to understand the requirements of the study and provide written information consent Exclusion Criteria: * Metastatic or locally advanced disease * HER2-positive tumors * Presence of other malignant or serious chronic diseases * Active infections * Previous stroke or heart attack, * Rheumatoid arthritis and other types of autoimmune diseases * Presence of a significant neurological deficit * Dementia * Allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits. * Allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant) * Use of lipid-lowering drugs (statins, Normolip) * Current use of warfarin or other anticoagulants * Corticosteroid therapy for the last month * Use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study